U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07227350) titled 'L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)' on Nov. 07.
Brief Summary: Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board. The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF, the secondary objectives of this study are to evaluate efficacy, safety and pharmacokinetics of immunocytokines. A minimum of 60 patients and a maximum of 180 evaluable patients will be randomized in a 1:1:1 ratio to one of the three different treatment arms o...